Recent Advances in Guillain-Barré Syndrome: Neurological Disorder, Pathophysiology, Diagnosis, Treatment, and Challenges

Guillain-Barré syndrome (GBS) is a rare and serious peripheral nervous system disorder triggered by an abnormal autoimmune response. It starts quickly with muscle weakness and can become paralyzing in the worst cases. Recent advances data have emerged on the pathophysiology, diagnosis, and treatment. The advances in immunology have emphasized auto-reactive of autoantibody-induced nerve injury's-cell involvement has also been identified, revealing new potential therapeutic targets. Advances in diagnostic tools such as metabolomic profiling and high-resolution imaging have improved early detection and differentiation of GBS subtypes. Intravenous immunoglobulin (IVIg) and plasma exchange are still the most important parts of treatment. However, researchers are looking into new treatments such as complement inhibitors, immune cell modulation, and cytokine-targeting therapies. Research on fluid biomarkers also promises better disease monitoring and prognosis. In spite of these advances, additional clinical trials are required to make these results applicable to standard clinical practice. This manuscript encapsulates the most recent progress in GBS research, highlighting the necessity for ongoing investigation of successful diagnostics and therapeutic approaches.